Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder that still lacks an efficient therapy. The barriers between the central nervous system (CNS) and the blood represent a major limiting factor to the development of drugs for CNS diseases, including ALS. Alterations of the...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/12/7/1071 |
| _version_ | 1797405903659466752 |
|---|---|
| author | Hugo Alarcan Yara Al Ojaimi Debora Lanznaster Jean-Michel Escoffre Philippe Corcia Patrick Vourc’h Christian R. Andres Charlotte Veyrat-Durebex Hélène Blasco |
| author_facet | Hugo Alarcan Yara Al Ojaimi Debora Lanznaster Jean-Michel Escoffre Philippe Corcia Patrick Vourc’h Christian R. Andres Charlotte Veyrat-Durebex Hélène Blasco |
| author_sort | Hugo Alarcan |
| collection | DOAJ |
| description | Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder that still lacks an efficient therapy. The barriers between the central nervous system (CNS) and the blood represent a major limiting factor to the development of drugs for CNS diseases, including ALS. Alterations of the blood–brain barrier (BBB) or blood–spinal cord barrier (BSCB) have been reported in this disease but still require further investigations. Interestingly, these alterations might be involved in the complex etiology and pathogenesis of ALS. Moreover, they can have potential consequences on the diffusion of candidate drugs across the brain. The development of techniques to bypass these barriers is continuously evolving and might open the door for personalized medical approaches. Therefore, identifying robust and non-invasive markers of BBB and BSCB alterations can help distinguish different subgroups of patients, such as those in whom barrier disruption can negatively affect the delivery of drugs to their CNS targets. The restoration of CNS barriers using innovative therapies could consequently present the advantage of both alleviating the disease progression and optimizing the safety and efficiency of ALS-specific therapies. |
| first_indexed | 2024-03-09T03:17:57Z |
| format | Article |
| id | doaj.art-6cf31497cc344b2bad20f73f3c23dd43 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-09T03:17:57Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-6cf31497cc344b2bad20f73f3c23dd432023-12-03T15:16:27ZengMDPI AGJournal of Personalized Medicine2075-44262022-06-01127107110.3390/jpm12071071Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?Hugo Alarcan0Yara Al Ojaimi1Debora Lanznaster2Jean-Michel Escoffre3Philippe Corcia4Patrick Vourc’h5Christian R. Andres6Charlotte Veyrat-Durebex7Hélène Blasco8Laboratoire de Biochimie et Biologie Moleculaire, CHRU Bretonneau, 2 Boulevard Tonnellé, 37000 Tours, FranceUMR 1253 iBrain, Université de Tours, Inserm, 10 Boulevard Tonnellé, 37000 Tours, FranceUMR 1253 iBrain, Université de Tours, Inserm, 10 Boulevard Tonnellé, 37000 Tours, FranceUMR 1253 iBrain, Université de Tours, Inserm, 10 Boulevard Tonnellé, 37000 Tours, FranceUMR 1253 iBrain, Université de Tours, Inserm, 10 Boulevard Tonnellé, 37000 Tours, FranceLaboratoire de Biochimie et Biologie Moleculaire, CHRU Bretonneau, 2 Boulevard Tonnellé, 37000 Tours, FranceLaboratoire de Biochimie et Biologie Moleculaire, CHRU Bretonneau, 2 Boulevard Tonnellé, 37000 Tours, FranceLaboratoire de Biochimie et Biologie Moleculaire, CHRU Bretonneau, 2 Boulevard Tonnellé, 37000 Tours, FranceLaboratoire de Biochimie et Biologie Moleculaire, CHRU Bretonneau, 2 Boulevard Tonnellé, 37000 Tours, FranceAmyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder that still lacks an efficient therapy. The barriers between the central nervous system (CNS) and the blood represent a major limiting factor to the development of drugs for CNS diseases, including ALS. Alterations of the blood–brain barrier (BBB) or blood–spinal cord barrier (BSCB) have been reported in this disease but still require further investigations. Interestingly, these alterations might be involved in the complex etiology and pathogenesis of ALS. Moreover, they can have potential consequences on the diffusion of candidate drugs across the brain. The development of techniques to bypass these barriers is continuously evolving and might open the door for personalized medical approaches. Therefore, identifying robust and non-invasive markers of BBB and BSCB alterations can help distinguish different subgroups of patients, such as those in whom barrier disruption can negatively affect the delivery of drugs to their CNS targets. The restoration of CNS barriers using innovative therapies could consequently present the advantage of both alleviating the disease progression and optimizing the safety and efficiency of ALS-specific therapies.https://www.mdpi.com/2075-4426/12/7/1071blood–brain barrierblood spinal cord barrieramyotrophic lateral sclerosisdrug design |
| spellingShingle | Hugo Alarcan Yara Al Ojaimi Debora Lanznaster Jean-Michel Escoffre Philippe Corcia Patrick Vourc’h Christian R. Andres Charlotte Veyrat-Durebex Hélène Blasco Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS? Journal of Personalized Medicine blood–brain barrier blood spinal cord barrier amyotrophic lateral sclerosis drug design |
| title | Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS? |
| title_full | Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS? |
| title_fullStr | Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS? |
| title_full_unstemmed | Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS? |
| title_short | Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS? |
| title_sort | taking advantages of blood brain or spinal cord barrier alterations or restoring them to optimize therapy in als |
| topic | blood–brain barrier blood spinal cord barrier amyotrophic lateral sclerosis drug design |
| url | https://www.mdpi.com/2075-4426/12/7/1071 |
| work_keys_str_mv | AT hugoalarcan takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT yaraalojaimi takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT deboralanznaster takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT jeanmichelescoffre takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT philippecorcia takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT patrickvourch takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT christianrandres takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT charlotteveyratdurebex takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT heleneblasco takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals |